By Boehringer Ingelheim | April 5, 2018BI, OSE Announce Partnership to Develop Pioneering Checkpoint Inhibitor
By Boehringer Ingelheim | March 19, 2018Expanded Indication for SPIRIVA Respimat for Patients 6 Years and Older
By Boehringer Ingelheim | January 10, 2018BeiGene, BI Agree on Commercial Supply Agreement for Anti-PD-1 Antibody
By Boehringer Ingelheim | November 3, 2017Boehringer Ingelheim, Dicerna Announce New Chronic Liver Disease R&D Deal
By Boehringer Ingelheim | October 13, 2017FDA Grants Priority Review to BI’s Gilotrif for Uncommon EGFR Mutations in Advanced NSCLC
By Boehringer Ingelheim | May 24, 2017IPF Patients Treated With Ofev Were Twice as Likely to Have Improved or Stable Lung Function
By Boehringer Ingelheim | January 3, 2017Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap